CONCORDIA PHARMACEUTICALS INC.

Concordia Pharmaceuticals Inc. specializes in the manufacturing of pharmaceutical preparations, focusing on the development, production, and regulatory compliance of finished dosage forms for government healthcare programs. Their technical expertise lies in adhering to current Good Manufacturing Practices (cGMP), managing cost recovery fee structures, and submitting detailed quarterly sales reports to ensure transparency and fiscal accountability in federal supply chains. The company demonstrates proficiency in navigating complex pharmaceutical procurement protocols, particularly those tied to federal cost-recovery mechanisms and reporting obligations under VA contracts. The Department of Veterans Affairs is the sole agency reflected in their award history, indicating a focused relationship centered on supplying pharmaceutical products to VA healthcare networks. Their work supports the VA’s mission to deliver consistent, high-quality medication access to veterans, likely involving branded or generic drug formulations distributed through VA pharmacies or specialty care channels. The nature of the recent award—a supplemental change to update cost recovery and reporting procedures—suggests an established, ongoing contractual relationship requiring strict compliance with federal financial and operational reporting standards. Concordia’s primary industry focus is NAICS 325412, which encompasses the formulation, blending, and packaging of medicinal drugs for human use. This places them squarely within the prescription pharmaceutical manufacturing sector, serving government health systems that require reliable, FDA-compliant drug production. Their market positioning is niche, emphasizing regulatory fidelity and administrative precision over broad commercial scale. As a 2L entity based in Bridgetown with no federal certifications listed, Concordia Pharmaceuticals operates as a small-scale manufacturer with a targeted presence in the federal pharmaceutical supply market. Their business model appears to prioritize compliance-driven contract execution over expansive certification portfolios, positioning them as a dependable, if specialized, supplier within the VA’s pharmaceutical acquisition ecosystem.